

# MaxCyte Inc

00:34 06 Sep 2018

## CAR-T therapies: All you wanted to know and were too afraid to ask

A new cutting-edge cancer treatment has been given the green light by the UK authorities after a deal over pricing was reached with its developer Novartis AG (SWX:NOVN).

Kymriah will be available for children and young people with aggressive leukaemia and is one of a new generation of treatments that uses the body's own immune system to tackle the killer disease.

It what's called a CART-T therapy, which stands for chimeric antigen receptor T-cell. As the name suggests the technology involves T-cells, white blood cells that help the immune system fight disease and infection.

### Re-engineering T-cells

CAR-T therapies re-engineer the blood to recognise cancer cells that have been hiding in the body that haven't been destroyed.

In clinical trials, Kymriah has proved effective, even in patients with the advanced form of the disease, so its rollout here in the UK will be welcomed by young leukaemia sufferers. But because it is a complex, personalised treatment the Novartis innovation is also eye-wateringly expensive with a list price of £282,000 per year.

And it isn't exactly a silver bullet. About 400 children are diagnosed with acute lymphoblastic leukaemia each year but nly 15 might be suitable for the CAR-T treatment.

### Hot area of research

Nevertheless, this area of immuno-oncology has become a popular field of research with UK companies at the forefront of the latest innovations.

Leading the pack is Autolus Therapeutics, a spin-out from University College London, which is now listed in the US with a market capitalisation in excess of US\$1bn.

Backed in its formative stages by Arix Biosciences and Neil Woodford's Patient Capital, it is running five CAR-T programmes covering six blood-borne cancers and solid tumour indications.

Smaller, with a market cap of US\$162m, but a potential pocket rocket is AIM-listed MaxCyte (LON:MXCT), which is gearing up to begin clinical trials of MCY-M11, a chimeric antigen receptor that targets solid tumours.

The phase I study will evaluate the safety of the potential treatment in people with relapsed, or difficult-to-treat ovarian cancer and peritoneal mesothelioma (a form of cancer that affects the abdomen). MaxCyte used its CARMA platform to develop the treatment.

### Unsung hero

Finally, Oxford Biomedica (LON:OXB) has been slightly overlooked in all the hullabaloo about Kymriah.

**Price:** 112.5

**Market Cap:** £64.56 m

### 1 Year Share Price Graph



### Share Information

**Code:** MXCT

**Listing:** AIM

**52 week High Low**  
198.5 95

**Sector:** Pharma & Biotech

**Website:** www.maxcyte.com

### Company Synopsis:

*We are a U. S. -based global company driving the acceleration of the discovery/development, manufacturing and commercialization of next-generation, cell-based medicines.*

action@proactiveinvestors.com.au

Yet without its technology, the treatment wouldn't exist. For OXB is the sole manufacturer of the lentiviral vector that encodes the CD19-directed chimeric antigen receptor in Kymriah.

For those who didn't understand the foregoing, a lentiviral vector is a method used to insert, modify or delete human genes.

Effectively, it re-programmes the T-cells.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 [action@proactiveinvestors.com.au](mailto:action@proactiveinvestors.com.au)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).